{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:16:28Z","timestamp":1790212588973,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,11,26]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We identified factors associated with thromboembolic and bleeding events in two contemporary cohorts of anticoagulated patients with atrial fibrillation (AF), treated with either vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOACs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective, multicentre observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>461 centres in seven European countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>5310 patients receiving a VKA (PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF), derivation cohort) and 3156 patients receiving a NOAC (PREFER in AF Prolongation, validation cohort) for stroke prevention in AF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>Risk factors for thromboembolic events (ischaemic stroke, systemic embolism) and major bleeding (gastrointestinal bleeding, intracerebral haemorrhage and other life-threatening bleeding).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of patients enrolled in the PREFER in AF registry was 72\u00b110 years, 40% were female and the mean CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc Score was 3.5\u00b11.7. The incidence of thromboembolic and major bleeding events was 2.34% (95% CI 1.93% to 2.74%) and 2.84% (95% CI 2.41% to 3.33%) after 1-year of follow-up, respectively.<\/jats:p><jats:p>Abnormal liver function, prior stroke or transient ischaemic attack, labile international normalised ratio (INR), concomitant therapy with antiplatelet or non-steroidal anti-inflammatory drugs, heart failure and older age (\u226575 years) were independently associated with both thromboembolic and major bleeding events.<\/jats:p><jats:p>With the exception of unstable INR values, these risk factors were validated in patients treated with NOACs (PREFER in AF Prolongation Study, 72\u00b19 years, 40% female, CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc 3.3\u00b11.6). For each single point decrease on a modifiable bleeding risk scale we observed a 30% lower risk for major bleeding events (OR 0.70, 95%\u2009CI 0.64 to 0.76, p&lt;0.01) and a 28% lower rate of thromboembolic events (OR 0.72, 95%\u2009CI 0.66 to 0.82, p&lt;0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Attending to modifiable risk factors is an important treatment target in anticoagulated AF patients to reduce thromboembolic and bleeding events. Initiation of anticoagulation in those at risk of stroke should not be prevented by elevated bleeding risk scores.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2018-022478","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T14:55:17Z","timestamp":1553957717000},"page":"e022478","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-0806","authenticated-orcid":false,"given":"Miklos","family":"Rohla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate B","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-9812","authenticated-orcid":false,"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Lucerna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,30]]},"reference":[{"key":"2024051713121267000_9.3.e022478.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2024051713121267000_9.3.e022478.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2024051713121267000_9.3.e022478.3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2016.0393","article-title":"Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation","volume":"1","author":"Freedman","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024051713121267000_9.3.e022478.4","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-05-0364"},{"key":"2024051713121267000_9.3.e022478.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.10.035"},{"key":"2024051713121267000_9.3.e022478.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"2024051713121267000_9.3.e022478.7","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009487"},{"key":"2024051713121267000_9.3.e022478.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"2024051713121267000_9.3.e022478.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000158925.12740.87"},{"key":"2024051713121267000_9.3.e022478.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.750000"},{"key":"2024051713121267000_9.3.e022478.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086"},{"key":"2024051713121267000_9.3.e022478.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"2024051713121267000_9.3.e022478.13","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi111"},{"key":"2024051713121267000_9.3.e022478.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"2024051713121267000_9.3.e022478.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.08.021"},{"key":"2024051713121267000_9.3.e022478.16","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.2.333"},{"key":"2024051713121267000_9.3.e022478.17","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.3.312"},{"key":"2024051713121267000_9.3.e022478.18","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.590257"},{"key":"2024051713121267000_9.3.e022478.19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.thromres.2014.05.034","article-title":"The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience","volume":"134","author":"Barnes","year":"2014","journal-title":"Thromb Res"},{"key":"2024051713121267000_9.3.e022478.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.08.1623"},{"key":"2024051713121267000_9.3.e022478.21","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut263"},{"key":"2024051713121267000_9.3.e022478.22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjmed.2014.05.003","article-title":"Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey","volume":"127","author":"Marcucci","year":"2014","journal-title":"Am J Med"},{"key":"2024051713121267000_9.3.e022478.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.019"},{"key":"2024051713121267000_9.3.e022478.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.024"},{"key":"2024051713121267000_9.3.e022478.25","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"2024051713121267000_9.3.e022478.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"2024051713121267000_9.3.e022478.27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.thromres.2014.06.003","article-title":"Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation","volume":"134","author":"Dzeshka","year":"2014","journal-title":"Thromb Res"},{"key":"2024051713121267000_9.3.e022478.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.10.001"},{"key":"2024051713121267000_9.3.e022478.29","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"key":"2024051713121267000_9.3.e022478.30","doi-asserted-by":"crossref","unstructured":"Szummer K , Gasparini A , Eliasson S , et al . Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017;6.doi:10.1161\/JAHA.116.004925","DOI":"10.1161\/JAHA.116.004925"},{"issue":"Suppl 1","key":"2024051713121267000_9.3.e022478.31","first-page":"4726","article-title":"Real-world adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: results of an international survey","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"2024051713121267000_9.3.e022478.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.06.024"},{"key":"2024051713121267000_9.3.e022478.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412223312502"},{"key":"2024051713121267000_9.3.e022478.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011170"},{"key":"2024051713121267000_9.3.e022478.35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a\u00a0\u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"2024051713121267000_9.3.e022478.36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.055079"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-022478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:48:08Z","timestamp":1715986088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-022478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,30]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/bmjopen-2018-022478"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-022478","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}